Lorazepam Related Compound D
USP/1370350 - United States Pharmacopeia (USP) Reference Standard
Synonym: 6-
CAS Number: 54643-79-7
Empirical Formula (Hill Notation): C15H8Cl2N2O2
Molecular Weight: 319.14
MDL Number: MFCD06203519
Linear Formula: C15H8Cl2N2O2
Product Type: Chemical
| API family | lorazepam |
| application(s) | pharmaceutical (small molecule) |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/C15H8Cl2N2O2/c16-8-5-6 |
| InChI key | WPSNLOADPUPVMP-UHFFFAOYSA |
| manufacturer/tradename | USP |
| SMILES string | OC(=O)c1nc(-c2ccccc2Cl)c3 |
| Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Application: | Lorazepam Related Compound D USP reference standard for use in specified quality tests and assays. Also used to prepare standard, system suitability, and peak identification solution during the assay, and impurity analysis by using liquid chromatography coupled with UV detector according to the given below monographs of United States Pharmacopeia (USP): • Lorazepam Oral Concentrate • Lorazepam Injection • Tetracaine and Menthol Ointment • Lorazepam Tablets |
| General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia   . |
| Other Notes: | Sales restrictions may apply. |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H319 - H413 |
| Precautionary statements | P273 - P301 + P312 + P330 - P305 + P351 + P338 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41116107 |